Shares of Cryolife Inc (NYSE:CRY) have received a consensus rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $26.88.
Several research firms have weighed in on CRY. Zacks Investment Research upgraded shares of Cryolife from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research note on Wednesday, May 30th. ValuEngine upgraded shares of Cryolife from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 23rd. Canaccord Genuity reiterated a “buy” rating and set a $28.00 target price (up previously from $25.00) on shares of Cryolife in a research note on Friday, March 9th. Finally, Northland Securities reiterated a “buy” rating and set a $23.50 target price on shares of Cryolife in a research note on Thursday, March 8th.
In other news, Director C Elkins Ronald sold 5,000 shares of the business’s stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $28.89, for a total transaction of $144,450.00. Following the completion of the transaction, the director now owns 70,997 shares of the company’s stock, valued at $2,051,103.33. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Amy Horton sold 4,000 shares of the business’s stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $25.94, for a total transaction of $103,760.00. Following the transaction, the chief accounting officer now directly owns 98,959 shares of the company’s stock, valued at approximately $2,566,996.46. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,191 shares of company stock valued at $1,332,075. 3.97% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas acquired a new position in shares of Cryolife during the fourth quarter valued at $197,000. Metropolitan Life Insurance Co. NY acquired a new position in shares of Cryolife during the fourth quarter valued at $203,000. Victory Capital Management Inc. boosted its holdings in shares of Cryolife by 98.4% during the first quarter. Victory Capital Management Inc. now owns 12,594 shares of the medical equipment provider’s stock valued at $253,000 after acquiring an additional 6,246 shares during the period. MetLife Investment Advisors LLC acquired a new position in shares of Cryolife during the fourth quarter valued at $330,000. Finally, Mackenzie Financial Corp boosted its holdings in shares of Cryolife by 42.4% during the fourth quarter. Mackenzie Financial Corp now owns 24,489 shares of the medical equipment provider’s stock valued at $469,000 after acquiring an additional 7,297 shares during the period. 67.56% of the stock is owned by institutional investors.
Shares of NYSE:CRY traded up $0.40 during midday trading on Monday, reaching $28.15. The company had a trading volume of 478,095 shares, compared to its average volume of 142,033. The company has a current ratio of 5.07, a quick ratio of 3.72 and a debt-to-equity ratio of 0.77. The firm has a market cap of $1.02 billion, a PE ratio of 84.09 and a beta of 0.78. Cryolife has a one year low of $16.80 and a one year high of $29.55.
Cryolife (NYSE:CRY) last issued its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.02. Cryolife had a negative net margin of 1.15% and a positive return on equity of 4.55%. The business had revenue of $61.95 million during the quarter, compared to analyst estimates of $60.30 million. During the same quarter in the previous year, the firm earned $0.09 earnings per share. The business’s revenue was up 37.5% compared to the same quarter last year. equities research analysts forecast that Cryolife will post 0.29 EPS for the current fiscal year.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.